Selective alpha-2A adrenergic agonist

Plain-language summaryIntrigue 62 / 100

Guanfacine is a more selective cousin of clonidine, originally a blood-pressure drug (Tenex) that found a second life as a non-stimulant ADHD medication (Intuniv, extended-release form). Where clonidine hits all three alpha-2 receptor subtypes broadly, guanfacine prefers the alpha-2A subtype, which is concentrated in the prefrontal cortex (the executive-function part of the brain). Activating it there appears to strengthen working memory and reduce impulsivity, which is the rationale for ADHD use. It is less sedating than clonidine at equivalent effect and is FDA-approved for ADHD in children and adolescents. Often combined with stimulants when stimulants alone are insufficient. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

51/100

Canonical alpha-2A PFC probe with mature ADHD evidence; novelty is low, precision is high

Look, guanfacine is a genuinely useful compound and we’re glad it’s in the library, but let’s be honest about where it sits in the research landscape. This is a 1970s Sandoz molecule, FDA-approved for hypertension in 1986, with the ADHD indication following in 2009 as Intuniv. The core chemistry and pharmacology have been understood for decades, and there’s no mystery left in the primary mechanism.

What keeps it interesting is the alpha-2A subtype selectivity story. Clonidine predates guanfacine and acts across 2A, 2B, and 2C subtypes with less discrimination; guanfacine runs roughly 25-fold selective for 2A over the other subtypes. That matters because alpha-2A receptors dominate the prefrontal cortex, where adrenergic tone directly modulates working memory and executive function through post-synaptic signaling that reduces cAMP and increases the signal-to-noise ratio of PFC pyramidal neurons. Amy Arnsten’s work at Yale is the anchor here, and her group has done the most rigorous mapping of how alpha-2A agonism strengthens PFC network firing without the sedation you get from clonidine at comparable doses.

As a bench tool, guanfacine is the reference compound for alpha-2A pharmacology in the PFC. If you’re running experiments on stress-induced working memory impairment, age-related cognitive decline, or the adrenergic circuitry underlying impulsivity, guanfacine is your cleanest available probe. That’s a real point in its favor, and we score bench utility accordingly.

The evidence base is mature and solid. Multiple phase 3 RCTs in pediatric ADHD, a clean safety profile relative to stimulant alternatives, and well-replicated preclinical work in non-human primates and rodent models going back decades. That said, the effect sizes in ADHD are modest compared to stimulants, and the translational signal, while real and confirmed, doesnt represent a paradigm-defining clinical outcome. It’s a solid, confirmed, specific effect; not a revolutionary one.

We think the honest limitation here is novelty. There’s not much territory left to explore in the core mechanism. New applications do surface, including PTSD (guanfacine for hyperarousal, with some promising small trials out of groups like Pitman’s at Harvard) and emerging work on stress-sensitization in substance use disorders, and those angles give the score a small lift. But for most bench programs that dont specifically need an alpha-2A probe, guanfacine isnt the compound that’s going to define a new research direction. It does a specific job extremely well, and if that job is yours, it belongs in your toolkit.

Novelty: 20
Mechanism promise: 42
In-category differentiation: 58
Evidence quality: 73
Translational signal: 67
Research bench value: 63

Rationale Guanfacine earns on differentiation and evidence as the canonical alpha-2A selective agonist and an FDA-approved compound with replicated ADHD trials, but a 1970s mechanism and fully mapped pharmacology hold novelty and mechanism scores low, producing a mid-tier overall that reflects its value as a precision tool rather than a research frontier.

Selective alpha-2A adrenergic agonist

A selective alpha-2A adrenergic agonist; an antihypertensive repurposed as a non-stimulant ADHD treatment with greater alpha-2A selectivity than clonidine.

Abstract

Guanfacine (N-{[2-(2,6-dichlorophenyl)acetyl]amino}guanidine; CAS 29110-47-2; molecular formula C9H9Cl2N3O; molecular weight 246.10) is a selective alpha-2A adrenergic agonist developed at Sandoz in the 1970s and approved by the FDA in 1986 under the trade name Tenex (immediate release) and 2009 as Intuniv (extended release for ADHD). Distinct from clonidine by greater alpha-2A subtype selectivity (approximately 25-fold over alpha-2B and alpha-2C); the alpha-2A subtype predominates in the prefrontal cortex where it modulates working memory and executive function, supporting the cognitive enhancement seen in ADHD. The CNS-prefrontal cortex effect is more pronounced than the cardiovascular effect at clinical ADHD doses. Plasma half-life is approximately 17 hours, supporting once-daily dosing in the ER formulation. Renal excretion is the principal clearance pathway. Approved for hypertension and (Intuniv) ADHD in children and adolescents. Used as the canonical alpha-2A selective agonist in prefrontal cortex pharmacology and ADHD research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-259Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Selective alpha-2A adrenergic agonist

Guanfacine

Abstract

Read the full monograph